Evercore ISI Group Raises Price Target for Twist Bioscience (TWS
Evercore ISI Group has raised its price target for Twist Bioscience (TWST) from $52.00 to $56.00, maintaining an 'Outperform' rating. This adjustment, made on April 6, 2026, reflects a positive outlook for the company. Twist Bioscience, which utilizes a disruptive DNA synthesis platform, has received several price target increases from other firms recently, indicating growing analyst confidence.
Evercore Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $56
Evercore has reiterated its Buy rating on Twist Bioscience (TWST.US) and increased its target price to $56. This indicates a positive outlook from the analyst firm regarding the company's future stock performance.
SG Americas Securities LLC Acquires 59,500 Shares of Twist Bioscience Corporation $TWST
SG Americas Securities LLC significantly increased its stake in Twist Bioscience Corporation (NASDAQ:TWST), acquiring an additional 59,500 shares in the fourth quarter, bringing its total holdings to 76,484 shares valued at $2.43 million. Other institutional investors also adjusted their positions, with several boosting their ownership. Despite missing Q4 EPS estimates, Twist Bioscience reported a 16.9% year-over-year revenue increase, with analysts issuing a consensus "Moderate Buy" rating and an average price target of $46.50.
Twist Bioscience Director Sells $51,000 in Shares
Twist Bioscience Corporation Director Melissa Starovasnik sold 1,000 shares of the company's stock for $51,000 on April 1, 2026. This transaction reduced her ownership stake by 3.74% and was executed under a pre-arranged 10b5-1 trading plan. She now directly owns 25,722 shares valued at approximately $1.31 million.
Insider Sell: Melissa Starovasnik Sells 1,000 Shares of Twist Bi
Melissa Starovasnik, a Director at Twist Bioscience Corp (TWST), sold 1,000 shares of the company on April 1, 2026, bringing her total ownership to 25,722 shares. This transaction is part of a pattern of insider selling at TWST, with 117 insider sells and no insider buys in the past year. Based on its GF Value, the stock is considered modestly overvalued.
Insider Selling: Twist Bioscience (NASDAQ:TWST) Director Sells 1,000 Shares of Stock
Twist Bioscience (NASDAQ:TWST) Director Melissa Starovasnik sold 1,000 shares of the company's stock on April 1st for $51,000, reducing her stake by 3.74%. The company, which is currently unprofitable, reported a slight EPS miss but revenue growth, and analysts generally rate it as a "Moderate Buy" with a consensus target price of $46.50. Institutional investors like Goldman Sachs and RBC have increased their holdings, despite the insider selling.
Director at Twist Bioscience (TWST) sells 1,000 shares in Rule 10b5-1 plan trade
Twist Bioscience director Melissa A. Starovasnik sold 1,000 shares of common stock at $51.00 per share on April 1, 2026, through an open-market transaction. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan established on November 22, 2025. Following the transaction, Starovasnik directly holds 25,722 shares of Twist Bioscience.
Twist Bioscience Corp. Trade Ideas — LS:A2N7L2
This article compiles various trade ideas and analyses for Twist Bioscience Corp. (LS:A2N7L2, NASDAQ:TWST) from different traders, offering both bullish and bearish perspectives. It highlights the company's groundbreaking DNA synthesis technology and its applications in medicine, industrial processes, and agriculture, while also discussing technical indicators like RSI, Aroon, and Stochastic for potential price movements. The ideas cover entry points, price targets, and assessments of the stock's long-term potential.
TWIST BIOSCIENCE CORP (1TWST.MI) Interactive Stock Chart
This page provides an interactive stock chart for TWIST BIOSCIENCE CORP (1TWST.MI) on Yahoo Finance. It displays the current stock price, recent performance, and a list of related news articles concerning the company's valuation, new product launches, and earnings reports. The page also includes broader market data.
TWST Should I Buy
An analysis of Twist Bioscience Corp (TWST) recommends a "Hold" for beginner long-term investors due to a mix of positive growth trends and bullish technicals, offset by significant hedge fund selling and weak financial performance. While analysts are raising price targets, the company is experiencing declining net income and EPS. The report details technical indicators, financial performance, and recent analyst ratings to support its cautious outlook.
Twist Bioscience Corp Stock: Pioneering DNA Synthesis for Biotech Innovation and Investor Opportunit
Twist Bioscience Corp (TWST) is a leader in synthetic DNA manufacturing, utilizing a silicon chip-based process to enable advancements in therapeutics, agriculture, and data storage. The company's scalable platform reduces costs and accelerates biotech workflows, positioning it strongly against competitors like IDT and GenScript. While offering significant growth opportunities for investors in the synthetic biology sector, the company faces risks including market competition, technology yield variability, and dependency on biopharma R&D cycles.
(TWST) Movement Within Algorithmic Entry Frameworks
Twist Bioscience Corporation (NASDAQ: TWST) shows near-term neutral sentiment but mid and long-term strength. The analysis identifies elevated downside risk and provides institutional trading strategies including long, momentum breakout, and short positions with specific entry, target, and stop-loss levels. Multi-timeframe signal analysis also details support and resistance levels across different time horizons.
Tudor Investment Corp ET AL Acquires Shares of 25,465 Twist Bioscience Corporation $TWST
Tudor Investment Corp ET AL has acquired a new position of 25,465 shares in Twist Bioscience (NASDAQ:TWST), valued at approximately $717,000. Other institutional investors like Goldman Sachs have also increased their holdings, while company insiders, including CFO Adam Laponis, have sold shares. Despite a 16.9% year-over-year revenue increase, Twist Bioscience remains unprofitable, with analysts holding a "Moderate Buy" consensus rating and a target price of $46.50.
Twist Bioscience Corp. Trade Ideas — BOATS:TWST
This article compiles various trade ideas and analyses for Twist Bioscience Corporation (TWST) from different traders on TradingView. It covers both bullish and bearish perspectives, utilizing technical indicators like RSI, Aroon, and Momentum, alongside fundamental analysis on EPS and sales growth. Many traders express optimism about TWST's innovative DNA synthesis technology and its potential applications in diverse fields, while others highlight risks associated with overbought conditions or lockup expirations.
Twist Bioscience Corp. Experiences Evaluation Revision Amid Mixed Market Indicators
Twist Bioscience Corp. has seen a recent stock price adjustment, trading at $44.53, down from $46.75, with mixed technical indicators. Despite a strong year-to-date return of 40.38% and a three-year return of 173.53%, outperforming the S&P 500, its five-year performance shows a significant decline, highlighting fluctuating market dynamics.
Twist Bioscience Corp Stock: Synthetic Biology Leader Driving DNA Innovation for Investors
Twist Bioscience Corp (TWST) is distinguished as a leader in synthetic biology through its high-throughput DNA synthesis platform, offering North American investors exposure to genomics and biotech innovation. The company utilizes a proprietary silicon-based technology, inspired by semiconductor manufacturing, for scalable and high-fidelity DNA production across therapeutics, agriculture, and industrial biotech, demonstrating a capital-light business model. While offering significant growth potential due to its technological moat and diverse applications, investors are advised to consider inherent biotech volatility, competitive pressures, and profitability timelines.
Twist Bioscience (NASDAQ:TWST) Given New $55.00 Price Target at Guggenheim
Guggenheim has raised its price target for Twist Bioscience (NASDAQ:TWST) to $55.00 from $50.00, maintaining a "buy" rating and suggesting a 23.13% upside. This adjustment follows the company reporting revenue of $103.7 million (up 16.9% year-over-year and above estimates) but missing EPS estimates at -$0.50. Despite insider sales, institutional investors like Goldman Sachs and RBC have increased their stakes in the company.
Vanguard (TWST) amendment shows 0 shares after Jan 12, 2026 realignment
The Vanguard Group filed an amendment to its Schedule 13G/A for Twist Bioscience Corp (TWST), reporting zero beneficial ownership after an internal realignment on January 12, 2026. This realignment means certain Vanguard subsidiaries will now report their ownership separately, in reliance on SEC Release No. 34-39538. The filing explicitly states 0 shares beneficially owned and 0% of the class for The Vanguard Group itself, indicating a change in reporting aggregation rather than a divestment.
Twist Biosciences: Keeping Synthetic Biology Alive
The article discusses the enduring presence of Twist Biosciences ($TWST) in the synthetic biology sector, highlighting its business divisions in DNA synthesis and protein solutions. It also addresses past accusations of a "ponzi-like scheme" by short-seller Scorpion, which Twist has largely overcome through consistent revenue growth and a clear path to profitability. The piece explores the evolving synthetic biology landscape, Twist's adapting thesis to incorporate AI and protein solutions, and its future prospects for continued growth and profitability.
Twist Bioscience Corp. Opens with 5.02% Gain, Outperforming S&P 500's 1.15% Increase
Twist Bioscience Corp. saw a 5.02% gain today, outperforming the S&P 500's 1.15% increase, despite a 7.47% decline over the past month. The company reported a 16.89% increase in net sales but has underperformed the market over the last year. While institutional ownership is high at 100%, indicating strong investor interest, the stock faces financial challenges with a negative return on equity and high price-to-book ratio.
Cathie Wood’s ARK sells Twist Bioscience and buys Circle Internet stock
Cathie Wood's ARK ETFs made significant trades on March 24, 2026, including a major purchase of 161,513 shares of Circle Internet Group Inc for over $20 million, indicating a continued interest in the company. Concurrently, ARK offloaded 190,100 shares of Twist Bioscience Corp, valued at nearly $8.5 million, marking it as the largest sale of the day and suggesting a strategic divestment. Other notable transactions included sales of Roku Inc, Teradyne Inc, Bullish, and purchases of 10X Genomics Inc, reflecting ARK's dynamic investment strategy in technology and biotech sectors.
Twist Bioscience (TWST) CEO sells shares to cover RSU tax bill
Twist Bioscience Corp (TWST) CEO Emily M. Leproust sold 1,742 shares of common stock at an average price of $43.7864 per share on March 20, 2026. This sale was a mandated "sell to cover" transaction to satisfy tax withholding obligations associated with the vesting of restricted stock units, not a discretionary trade. Following the transaction, Leproust still holds 858,887 shares directly, along with various employee stock options.
Twist Bioscience (TWST) SVP sells 297 shares in tax sell-to-cover
Twist Bioscience Corp's Senior Vice President of Human Resources, Paula Green, sold 297 shares of common stock at $43.7864 per share. This transaction was a mandated "sell to cover" sale to satisfy tax withholding obligations on vested Restricted Stock Units and was not a discretionary trading decision. Following the sale, Green directly holds 124,104 shares of Twist Bioscience common stock.
Tax-driven share sale by Twist Bioscience (TWST) officer Dennis Cho disclosed
Twist Bioscience (TWST) officer Dennis Cho reported a mandated sale of 354 shares of Common Stock at $43.7864 per share. This "sell-to-cover" transaction was necessary to fulfill tax withholding obligations on vesting Restricted Stock Units, not a discretionary sale. Following this transaction, Cho directly holds 137,903 Twist Bioscience shares.
JPMorgan Chase & Co. Sells 420,892 Shares of Twist Bioscience Corporation $TWST
JPMorgan Chase & Co. reduced its stake in Twist Bioscience Corporation by 29.2%, selling 420,892 shares and retaining a holding valued at approximately $28.65 million. Despite this reduction, analysts maintain a "Moderate Buy" rating with a consensus target price of $45.88. The company recently reported a quarterly EPS miss but saw a 16.9% increase in revenue, while insiders, including the CFO and CEO, have also sold shares.
Twist Bioscience Corp stock faces scrutiny amid insider selling and biotech sector volatility
Twist Bioscience Corp is under scrutiny due to recent insider stock sales by top executives, occurring after a significant stock price surge. Despite these sales, which are common after biotech rallies and often linked to personal financial planning, the company's strategic partnerships, solid cash position, and positive analyst sentiment suggest strong long-term potential in synthetic biology. Investors are keen to monitor its financial health and progress in AI-driven drug discovery amidst biotech sector volatility.
If You Invested $1,000 in Twist Bioscience (TWST)
This article analyzes the historical performance of investing $1,000 in Twist Bioscience (TWST) over different periods, including 1, 5, and 10 years, and provides a year-by-year return breakdown. It also offers an in-depth overview of Twist Bioscience, detailing its synthetic biology platform, products, business model, industry context, and its focus on biosecurity. The company utilizes a silicon-based DNA synthesis platform for various applications in medicine, agriculture, industrial chemicals, and defense.
Twist Bioscience Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics
Twist Bioscience Corp., a small-cap biotechnology firm, is experiencing notable stock volatility currently priced at $44.80. Despite a challenging five-year performance with a 63.96% decline, the company has shown strong year-to-date returns of 41.24%, outperforming the S&P 500's decline. Technical indicators suggest a potential recovery phase, though there is a mixed outlook with bullish weekly signals and a bearish monthly outlook from the KST.
Twist Bioscience Q1 2026 earnings preview
This article provides an earnings preview for Twist Bioscience's Q1 2026 results. It focuses on the upcoming financial report and what analysts and investors might expect from the company's performance.
Insider sale notice — TWST (NASDAQ: TWST) 1,742 shares reported
A Form 144 filing indicates a proposed sale of 1,742 shares of Twist Bioscience Corp (TWST) common stock by an insider, linked to restricted stock vesting on March 19, 2026. The filing also details multiple past dispositions by Emily M. Leproust, including sales on December 22, 2025, February 3, 2026, February 23, 2026, and March 6, 2026, ranging from 1,605 to 7,205 shares. This notice provides no details on cash flow treatment, buyer information, or specific sale prices, which would require further documentation.
TWST (NASDAQ: TWST) files Rule 144 for 354 shares; insider sales detailed
Twist Bioscience Corp (NASDAQ: TWST) has filed a Rule 144 notice for the proposed resale of 354 common shares linked to restricted stock vesting on March 19, 2026. The filing also details multiple open-market sales by insider Dennis H. Cho between December 2025 and March 2026. These transactions include sales of 324, 1,099, 5,000, 844, and 425 shares, with corresponding gross proceeds listed for each trade.
Paula Green sells 39,404 TWST shares (NASDAQ: TWST) in Form 144
Paula Green, an insider at Twist Bioscience Corp (NASDAQ: TWST), reported multiple sales of company shares via a Form 144 filing. The largest transaction involved 39,404 shares sold on February 17, 2026, for over $2 million. The filing also detailed other sales and the vesting of 297 restricted shares as compensation.
Twist Bioscience director chess sells $470,000 in shares
Twist Bioscience Director Robert Chess sold 10,000 shares of common stock for $470,000 and exercised options to purchase an equal number of shares for $118,900. These transactions were executed under a pre-arranged trading plan, increasing his direct and indirect holdings. The sale follows a significant stock rally and coincides with the company's recent Q1 2026 earnings report, which showed revenue growth but missed EPS forecasts, and a new licensing agreement with Invenra Inc.
Robert Chess Sells 10,000 Shares of Twist Bioscience (NASDAQ:TWST) Stock
Robert Chess, a director at Twist Bioscience (NASDAQ:TWST), sold 10,000 shares of company stock for $470,000 on March 17, 2026, reducing his stake by over 32%. This sale comes as the company reported a Q4 EPS miss and revenue increase, with analyst sentiment being mixed to modestly positive. The stock traded at $44.80 mid-day, below the consensus price target of $45.88.
Twist Bioscience director chess sells $470,000 in shares
Robert Chess, a director at Twist Bioscience Corp (NASDAQ:TWST), sold 10,000 shares of common stock for $470,000 on March 17, 2026. This transaction followed his exercise of options to purchase the same number of shares at a lower price. The sale was executed under a pre-arranged trading plan, and Chess continues to hold a significant number of shares both directly and indirectly.
Twist Bioscience (TWST) director’s 10b5-1 option exercise and 10K share sale
Twist Bioscience director Robert Chess exercised options for 10,000 shares of common stock at $11.89 per share and simultaneously sold those 10,000 shares at $47.00 per share. These transactions were pre-arranged under a Rule 10b5-1 trading plan adopted in December 2025. After the sale, Chess retains substantial direct and indirect holdings in the company, amounting to 21,084 direct shares and 42,528 indirect shares through a trust.
TWST SEC Filings - Twist Bioscience 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Twist Bioscience (TWST) SEC filings, including annual 10-K reports, quarterly 10-Q statements, 8-K material event disclosures, and insider trading forms. It features AI-powered summaries to help investors quickly interpret complex documents and real-time updates from EDGAR. Recent filings detail "sell-to-cover" insider transactions related to tax withholding for vested restricted stock units by executives.
Fidelity proposes sale of 10,000 TWST shares (TWST) under Form 144
Fidelity Brokerage Services LLC has filed a Form 144 indicating a proposed resale of 10,000 shares of Twist Bioscience Corp (TWST) common stock on March 17, 2026, with an aggregate value of $470,000. This filing also disclosed a separate sale by Robert B. Chess of 2,184 shares on February 13, 2026, for $105,401.37. Both transactions are linked to an option granted on September 13, 2018, and specify cash as the distribution method.
TWST SEC Filings - Twist Bioscience 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Twist Bioscience (NASDAQ: TWST) SEC filings, including annual 10-K, quarterly 10-Q, material event 8-K, and insider trading forms. It serves as a valuable resource for investors and traders to review the biotech company's financial performance, governance changes, and other material information. The platform also offers AI-powered summaries and real-time updates to help users quickly interpret complex regulatory documents and track insider activity.
Twist Bioscience Corp (TWST) Trading 4.44% Higher on Mar 16
Twist Bioscience Corp (TWST) saw its shares surge by 4.44% on March 16, closing at $45.20. The company's stock is currently 21.91% below its 52-week high but 93.99% above its 52-week low. Analysts have an average one-year price target of $50.60 for TWST, indicating an 11.95% upside from its current price, with a consensus "Outperform" rating.
Twist Bioscience Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics
Twist Bioscience Corp. has undergone a stock evaluation revision due to fluctuating market conditions. The stock shows a modest year-to-date increase of 36.44%, outperforming the S&P 500, but has declined significantly by -69.39% over the past five years, contrasting sharply with broader market growth. Technical indicators suggest cautious optimism with mixed bullish and bearish signals.
TWST SEC Filings - Twist Bioscience 10-K, 10-Q, 8-K Forms
This article provides an overview of Twist Bioscience (TWST) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights recent insider sales by key executives to cover RSU taxes and mentions the company's focus on synthetic DNA tools. The platform offers AI-powered summaries to help investors quickly understand these regulatory documents.
First Light Asset Management LLC Increases Position in Twist Bioscience Corporation $TWST
First Light Asset Management LLC increased its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 26.4% in the third quarter, making it their 9th largest holding. Other institutional investors like ARK Investment Management, Artisan Partners, and EdgePoint Investment Group also significantly increased their positions. Despite missing analyst EPS consensus, Twist Bioscience reported a revenue increase and holds a "Moderate Buy" consensus rating from analysts, though some insiders have recently sold shares.
Twist Bioscience Corporation $TWST Shares Acquired by EdgePoint Investment Group Inc.
EdgePoint Investment Group Inc. significantly increased its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 71.1% in the third quarter, now holding 4,082,319 shares valued at $114.9 million, making it their 22nd largest holding. Despite missing EPS estimates in its latest quarter, Twist Bioscience exceeded revenue expectations with 16.9% year-over-year growth. Analyst sentiment is generally positive with a "Moderate Buy" consensus rating and a $45.88 price target.
Twist Bioscience Stock Hits Day Low of $42.52 Amid Price Pressure
Twist Bioscience Corp. (TWST) stock has dropped by 8.19% to an intraday low of $42.52, significantly underperforming the S&P 500 on the same day. Despite a challenging recent performance with weekly and monthly declines, the stock shows a positive year-to-date increase of 35.62%. The company, with a market capitalization of $2,979 million and high institutional interest, faces financial challenges reflected in its negative return on equity and high price-to-book ratio.
Tax-related share sale by Twist Bioscience (TWST) accounting chief disclosed
Twist Bioscience's Chief Accounting Officer, Robert F. Werner, reported a mandated "sell to cover" transaction, disposing of 246 shares of common stock at $46.426 per share on March 6, 2026. This sale was non-discretionary and required to cover tax withholding obligations associated with the vesting of Restricted Stock Units. After the transaction, Werner beneficially held 54,799 shares.
Twist Bioscience (NASDAQ:TWST) Insider Sells $19,732.75 in Stock
Twist Bioscience insider Dennis Cho sold 425 shares of the company's stock for $19,732.75 on March 6, 2026, reducing his total holdings to 138,257 shares. This sale follows larger transactions in February and December. The company recently reported a quarterly EPS miss but revenue beat, and analysts have a "Moderate Buy" rating with a consensus price target around $45.88.
Emily Leproust Sells 2,423 Shares of Twist Bioscience (NASDAQ:TWST) Stock
Emily Leproust, CEO of Twist Bioscience (NASDAQ:TWST), sold 2,423 shares of the company's stock on March 6th for approximately $112,500, reducing her stake by 0.28%. This insider sale occurred shortly after Twist Bioscience reported a quarterly EPS miss despite beating revenue expectations, which led to a 6.1% drop in its stock price. Analysts generally rate TWST as a "Moderate Buy" with an average price target of $45.88, reflecting mixed sentiments following recent financial performance and insider trading activity.
Twist Bioscience Corp (TWST) Trading Down 4.49% on Mar 10
Twist Bioscience Corp (TWST) experienced a 4.49% drop in mid-day trading on March 10, reaching an intraday low of $46.00 before closing at $46.16. Despite this dip, the stock remains 98.11% above its 52-week low. Analyst forecasts show an average target price of $50.60, suggesting a potential upside of 9.62%, and brokerage firms rate it as "Outperform."
American Century Companies Inc. Sells 26,320 Shares of Twist Bioscience Corporation $TWST
American Century Companies Inc. reduced its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 3.0% in the third quarter, selling 26,320 shares but still holding 838,064 shares valued at $23.58 million. Despite this trimming, analyst sentiment for TWST remains a "Moderate Buy" with an average price target of $45.88, while the company reported a quarterly EPS of -$0.50, missing analyst estimates. Insider transactions also show recent sales by the CFO and a Director, totaling over 36,000 shares.
